Swedish biotech companies have a broad and varied product pipeline that is attracting attention from venture capitalists and pharmaceutical companies.
News|Articles|February 1, 2002
- Pharmaceutical Technology-02-02-2002
- Volume 26
- Issue 2
Outsourcing Outlook
Author(s)Jim Miller
The author discusses current economic times and conditions for large pharmaceutical companies.
Advertisement
Articles in this issue
over 24 years ago
Using Earned-Value Analysis to Better Manage Projectsover 24 years ago
Microbial Bioburden on Oral Solid Dosage Formsover 24 years ago
Modernizing Pharmaceutical ManufacturingAdvertisement
Related to this article
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Shilpa Pharma Lifesciences Limited will launch a new small-molecule CDMO at CPHI Milan in October.
This article explains the 4 shifts enabling faster, lower-risk, commercially successful biologics technology transfer.
Advertisement
Advertisement